Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > This stock has dropped the whole year

<< Previous

Bullboard Posts

Next >>

Comment by Ryeman40on Dec 19, 2020 11:32pm

197 Views

Post# 32148409

RE:This stock has dropped the whole year

YukonJezza wrote:
it is one of the few stocks that did not double or triple since Mar 2020. It dropped 50%. So flakey promises of tripling buy beginning 2021 makes me doubt management. Sorry..being realistic. Think of the money you could have gained. ..if this doesn't even move the interest needle at all time market highs......what's going to change on global market consolidation.

Technically it more than doubled from march 16,2020 $3.95 or .395 to June 1,2020 $8.90 or .890. If you were just playing the runup to phase 2 you would of made some very good money.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China